PGR and neoplasm: Currently, BC treatment choice is based on the hormone receptor expression of the tumour, with hormone- and receptor-targeted therapies achieving long-term outcomes for oestrogen receptor-positive (ER+), progesterone receptor-positive (PR+) and/or human epidermal growth factor receptor-positive (HER2+) BC [2].